Diabetes

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.

Hypertension and obstructive sleep apnea are considered independent risk factors for cardiovascular diseases as well as diabetes.

Further studies are needed to further confirm the association between glucagon-like peptide 1 medication and reductions in dementia risk.

Type 1 diabetes can cause long-term complications, including the development of autoimmune diseases.

Clinical pharmacists counsel patients during the intervention and make informed medication changes based on the data received from continuous glucose monitoring (CGM).

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

All 3 types of virtual diabetes self-management interventions lead to better results in hemoglobin A1c over a 6-month period.

The integration of CGM into pharmacy practice represents a significant opportunity for pharmacists to provide enhanced patient care.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, associate director of experiential education at the College of Pharmacy at Midwestern University, also addresses personalized care and the expanding responsibilities of pharmacists.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, associate director of experiential education at the College of Pharmacy at Midwestern University, discusses recent advancements in diabetes care.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the various errors patients experience when using CGM devices.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, compare patients’ diabetes outcomes in clinical and community pharmacy settings.

Control-IQ+ was associated with a greater reduction in glycated hemoglobin compared to a continuous glucose monitor alone.

A recent study found that continuous glucose monitors could help improve patient comfort, reduce resource use, and improve outcomes.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

However, investigators did not determine the association between compatibility status and loss-of-signal alarms.